NL-OMON55904
Recruiting
Not Applicable
Metabolic Imaging to Improve Patient-Specific Therapy Outcome - MAESTRO
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 70
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with liver metastasis of gastro\-oesophageal cancer, with histological
- •or cytological proof of
- •metastasis or a high suspicion on CT imaging whom are scheduled for first line
- •palliative chemotherapy.
- •2\. Informed consent
Exclusion Criteria
- •Any psychological, familial, sociological or geographical condition potentially
- •hampering adequate informed consent or compliance with the study protocol.
- •Contra\-indications for MR scanning, including patients with a pacemaker,
- •cochlear implant or neurostimulator; patients with non\-MR compatible metallic
- •implants in their eye, spine, thorax or abdomen; or a non\-MR compatible
- •aneurysm clip in their brain; patients with claustrophobia; patient with an
- •abdominal circumference which exceeds MRI\-bore circumference.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Studies on the usefulness of the metabolic imaging against arterial chemoradiation therapy for head and neck cancerhead and neck cancerJPRN-UMIN000005000Tokushima University Hospital Department of Radiology10
Active, not recruiting
Phase 1
Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trialEUCTR2017-000123-28-FRInstitut Jules Bordet185
Active, not recruiting
Phase 1
Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trialesophageal ADC, esophageal SCC, Cholangiocarcinoma, urothelial cancer (progressive after immunotherapy), or endometrial cancerMedDRA version: 20.0Level: LLTClassification code 10055458Term: Esophageal adenocarcinomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10055476Term: Esophageal squamous cell carcinomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10008595Term: Cholangiocarcinoma NOSSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10014735Term: Endometrial cancer NOSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-000123-28-BEInstitut Jules Bordet185
Recruiting
Not Applicable
MAESTRO Study: Metabolic Imaging to Improve Patient-Specific Therapy OutcomesGastrointestinal Cancer MetastaticNCT04534543Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)70
Terminated
Not Applicable
Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CARectal CancerNCT00394615Stanford University15